Determination of whole body circadian phase in lung cancer patients: Melatonin vs. cortisol

Cancer Epidemiology

Volumn 36, Issue 1, 2012, Pages

  Mazzoccoli, Gianluigi ^a   Giuliani, Francesco ^a   Sothern, Robert B ^b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Circadian rhythmicity; Cortisol; Fractional variation; Marker rhythm; Melatonin

Indexed keywords

HYDROCORTISONE; MELATONIN;

ADULT; AROUSAL; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CHRONOBIOLOGY; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONTROLLED STUDY; DARKNESS; HORMONE RELEASE; HUMAN; HYDROCORTISONE BLOOD LEVEL; LUNG NON SMALL CELL CANCER; MALE; METHODOLOGY; NIGHT; OSCILLATION; PRIORITY JOURNAL;

ADULT; AGED; CASE-CONTROL STUDIES; CIRCADIAN RHYTHM; HUMANS; HYDROCORTISONE; LUNG NEOPLASMS; MALE; MELATONIN; MIDDLE AGED; NEOPLASM STAGING;

EID: 84855840998     PISSN: 18777821     EISSN: 1877783X     Source Type: Journal    
DOI: 10.1016/j.canep.2011.06.005     Document Type: Article

References (43)

1. Hsing A.W., Meyer T.E., Niwa S., Quraishi S.M., Chu L.W. Measuring serum melatonin in epidemiologic studies. Cancer Epidemiol Biomarkers Prev 2010, 19(4):932-937.
2. Dana K., Mirick D.K., Davis S. Melatonin as a biomarker of circadian dysregulation. Cancer Epidemiol Biomarkers Prev 2008, 17(12):3306-3313.
3. Schernhammer E.S., Laden F., Speizer F.E., Willett W.C., Hunter D.J., Kawachi I., et al. Rotating night shifts and risk of breast cancer in women participating in the Nurses' Health Study. J Natl Cancer Inst 2001, 93:1563-1568.
4. Schernhammer E.S., Laden F., Speizer F.E., Willett W.C., Hunter D.J., Kawachi I., et al. Night-shift work and risk of colorectal cancer in the Nurses' Health Study. J Natl Cancer Inst 2003, 95:825-828.
5. Davis S., Mirick D.K., Stevens R.G. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 2001, 93:1557-1562.
6. Hansen J. Light at night, shift work, and breast cancer risk. J Natl Cancer Inst 2001, 93:1513-1515.
7. Pukkala E., Aspholm R., Auvinen A., Eliasch H., Gundestrup M., Haldorsen T. Incidence of cancer among Nordic airline pilots over five decades: occupational cohort study. BMJ 2002, 325:567-571.
8. Rafnsson V., Tulinius H., Jonasson J.G., Hrafnkelsson J. Risk of breast cancer in female flight attendants: a population-based study (Iceland). Cancer Causes Control 2001, 12:95-101.
9. Arendt J. Melatonin and human rhythms. Chronobiol Int 2006, 23:21-37.
10. Brown E.N., Luithardt H. Statistical model building and model criticism for human circadian data. J Biol Rhythms 1999, 14(6):609-616.
11. Veldhuis J.D., Keenan D.M., Pincus S.M. Motivations and methods for analyzing pulsatile hormone secretion. Endocr Rev 2008, 29(7):823-864.
12. St Hilaire M.A., Gronfier C., Zeitzer J.M., Klerman E.B. A physiologically based mathematical model of melatonin including ocular light suppression and interactions with the circadian pacemaker. J Pineal Res 2007, 43(3):294-304.
13. Cassone V.M., Natesan A.K. Time and time again: the phylogeny of melatonin as a transducer of biological time. J Biol Rhythms 1997, 12:489-497. [review].
14. Arendt J. The pineal gland, circadian rhythms and photoperiodism. Physiology and pharmacology of biological rhythms 1997, 375-414. Springer-Verlag, Berlin. P.H. Redfern, B. Lemmer (Eds.).
15. Reiter R.J. Normal patterns of melatonin levels in the pineal gland and body fluids of humans and experimental animals. J Neural Transm 1986, 21(Suppl.):35-54.
16. Reiter R.J. Pineal melatonin: cell biology of its synthesis and its physiological interactions. Endocr Rev 1991, 12:151-179.
17. Rollag M.D., Berson D.M., Provencio I. Melanopsin, ganglion-cell photoreceptors, and mammalian photoentrainment. J Biol Rhythms 2003, 18:227-234.
18. Berson D.M., Dunn F.A., Takao M. Phototransduction by retinal ganglion cells that set the circadian clock. Science 2002, 295:1070-1073.
19. Lewy A.J., Sack R.L. The dim light melatonin onset as a marker for circadian phase position. Chronobiol Int 1989, 6:93-102.
20. Klerman E.B., Gershengorn H.B., Duffy J.F., Kronauer R.E. Comparisons of the variability of three markers of the human circadian pacemaker. J Biol Rhythms 2002, 17:181-193.
21. Pandi-Perumal S.R., Smits M., Spence W., Srinivasan V., Cardinali D.P., Lowe A.D., et al. Dim light melatonin onset (DLMO): a tool for the analysis of circadian phase in human sleep and chronobiological disorders. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:1-11.
22. Van Cauter E. Diurnal and ultradian rhythms in human endocrine function: a minireview. Horm Res 1990, 34:45-53.
23. Gusenoff J.A., Harman S., Veldhuis J.D., Jayme J.J., Clair St., Munzer C., et al. GH secretory dynamics, and their interrelationships, in healthy aged women and men. Am J Physiol Endocrinol Metab 2001, 280:E616-E625.
24. Haus E. Chronobiology in the endocrine system. Adv Drug Deliv Rev 2007, 59:985-1014.
25. Mazzoccoli G., Giuliani F., Sothern R.B. A methodology to evaluate dynamics and periodicity of hormone secretion. J Biol Regul Homeost Agents 2011, 25(2):235-242.
26. Mermall H., Sothern R.B., Kanabrocki E.L., Quadri S.F., Bremner F.W., Nemchausky B.M., et al. Temporal circadian) and functional relationship between prostate-specific antigen and testosterone in healthy men. Urology 1995, 46(1):45-53.
27. Nelson W., Tong Y.L., Halberg F. Methods for cosinor rhythmometry. Chronobiologia 1979, 6:305-323.
28. Mojón A., Fernández J.R., Hermida R. Chronolab: an interactive software package for chronobiologic time series analysis written for the Macintosh computer. Chronobiol Int 1992, 9:403-412.
29. Brown E.N., Meehan P.M., Dempster A.P. A stochastic differential equation model of diurnal cortisol patterns. Am J Physiol Endocrinol Metab 2001, 280:E450-E461.
30. Brown E.N., Choe Y., Shanahan T.L., Czeisler C.A. A mathematical model of diurnal variations in human plasma melatonin levels. Am J Physiol 1997, 272(3 Pt 1):E506-E516.
31. Benloucif S., Burgess H.J., Klerman E.B., Lewy A.J., Middleton B., Murphy P.J., et al. Measuring melatonin in humans. J Clin Sleep Med 2008, 4:66-69.
32. Brivio F., Fumagalli L., Fumagalli G., Pescia S., Brivio R., Di Fede G., et al. Synchronization of cortisol circadian rhythm by the pineal hormone melatonin in untreatable metastatic solid tumor patients and its possible prognostic significance on tumor progression. In Vivo 2010, 24:239-241.
33. Reiter R.J. The pineal gland and melatonin in relation to aging: a summary of the theories and of the data. Exp Gerontol 1995, 30(3-4):199-212. Review.
34. Waldhauser F., Kovács J., Reiter E. Age-related changes in melatonin levels in humans and its potential consequences for sleep disorders. Exp Gerontol 1998, 33(7-8):759-772. [review].
35. Mahlberg R., Tilmann A., Salewski L., Kunz D. Normative data on the daily profile of urinary 6-sulfatoxymelatonin in healthy subjects between the ages of 20 and 84. Psychoneuroendocrinology 2006, 31(5):634-641.
36. Mormont M.C., Hecquet B., Bogdan A., Benavides M., Touitou Y., Lévi F. Non-invasive estimation of the circadian rhythm in serum cortisol in patients with ovarian or colorectal cancer. Int J Cancer 1998, 78:421-424.
37. Tan D.X., Manchester L.C., Hardeland R., Lopez-Burillo S., Mayo J.C., Sainz R.M., et al. Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res 2003, 34:75-78. [review].
38. Vijayalaxmi, Thomas C.R., Reiter R.J., Herman T.S. Melatonin: from basic research to cancer treatment clinics. J Clin Oncol 2002, 20:2575-2601. [review].
39. Hu S., Shen G., Yin S., Xu W., Hu B. Melatonin and tryptophan circadian profiles in patients with advanced non-small cell lung cancer. Adv Ther 2009, 26(9):886-892.
40. Reiter R.J., Tan D.X., Sainz R.M., Mayo J.C., Lopez-Burillo S. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 2002, 54:1299-1321. [review].
41. Lissoni P., Brivio F., Fumagalli L., Messina G., Vigoré L., Parolini D., et al. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors. Anticancer Res 2008, 28(2B):1377-1381.
42. Ohdo S. Chronotherapeutic strategy: rhythm monitoring, manipulation and disruption. Adv Drug Deliv Rev 2010, 62(9-10):859-875.
43. Lévi F., Okyar A., Dulong S., Innominato P.F., Clairambault J. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol 2010, 50:377-421.